October 19, 2020

Volume X, Number 293

October 16, 2020

Subscribe to Latest Legal News and Analysis

DOJ Announces to the Supreme Court That it Will Seek to Dismiss False Claims Act Case, and Affirms Position on Materiality Under Escobar

The United States Department of Justice (DOJ) filed an amicus curiae brief with the Supreme Court on November 30, 2018 in a closely watched False Claims Act (FCA) lawsuit, after the Supreme Court asked for the Solicitor General's views. In the brief, DOJ explained its position on the FCA’s frequently litigated “materiality” standard. But DOJ also stunned observers by advising the Supreme Court that, if the Supreme Court agrees with its view that the case should not be dismissed on materiality grounds but remands the case to the district court, DOJ will seek to dismiss the long-running qui tam FCA lawsuit because the case is “not in the public interest.”  

DOJ’s amicus brief is particularly notable because it addresses two developing areas of FCA law and practice: the evolving analysis of “materiality” under Universal Health Services, Inc. v. United States ex rel. Escobar, 136 S. Ct. 1989 (2016) (“Escobar”), and DOJ’s statutory right to seek dismissal of declined FCA cases.  To our knowledge, DOJ has never invoked this authority, or signaled it would, initially at the Court of Appeals or Supreme Court level.  In January 2018, DOJ signaled in a new policy memo that it would more routinely consider invoking this authority at the time qui tam filing are declined, but few expected this dramatic move.

Relators’ FCA allegations

Relators filed this qui tam FCA lawsuit in 2010. According to relators, defendant Gilead Sciences, Inc. allegedly represented to the FDA in its New Drug Applications for three HIV drugs that it would obtain an active ingredient for these drugs, called FTC, from specific, approved facilities. Relators contend that defendant obtained FTC from an unapproved manufacturing facility in China. Relators further allege that when defendant later sought supplemental approval from FDA to use the facility to manufacture FTC, which FDA granted, the submission to FDA seeking approval purportedly contained false information. Defendant stopped using the facility in 2011.

Relators allege that drugs that contained FTC sourced from the Chinese facility from the outset were not eligible for reimbursement from government health care programs.   Further, Relators allege that, even though FDA later approved the facility,  FDA would not have approved it absent the allegedly false information.

Gilead argues that the alleged misstatements are immaterial, as the government know about the allegations since at least 2010, issued a warning letter, and inspected its facilities.  With this knowledge, FDA never withdrew its approval of the drugs, and the government continued to pay for the medications.  At the least, these facts should provide a strong presumption of immateriality that the Relators have failed to overcome in pleadings.

Prior decisions in the case

DOJ declined to intervene in the FCA lawsuit, and relators pressed forward with the FCA case on their own. Defendant moved to dismiss relators’ claims, and the district court dismissed relators’ FCA complaint (before the Supreme Court decided Escobar). Relators appealed to the Ninth Circuit Court of Appeals.  DOJ submitted a brief to the Ninth Circuit as amicus curiae supporting reversal of the district court. 

The Ninth Circuit reversed the district court, thus allowing relators’ FCA claims to proceed to discovery. Among other reasons, the Ninth Circuit found that relators had adequately alleged “materiality” under the FCA.

Under the FCA, “a misrepresentation about compliance with a statutory, regulatory, or contractual requirement must be material to the Government’s payment decision in order to be actionable.” Escobar, 136 S. Ct. at 2002. Whether a misrepresentation is material turns on its “effect on the likely or actual behavior of the recipient of the alleged misrepresentation.” Id.

Defendant asserted that the alleged FDA violations were not material to the government’s decision to pay for the drugs because the government continued payment for the medications, even after it purportedly knew of defendant’s alleged violations.  But the Ninth Circuit disagreed, finding that “to read too much into the FDA’s continued approval—and its effect on the government’s payment decision—would be a mistake.” In addition, the court identified a dispute over the extent and timing of the government’s “actual knowledge” of defendant’s alleged violations.

Gilead asked the Supreme Court to take the case, and the Supreme Court in April 2018 sought the Solicitor General’s views.  In its brief, DOJ urged the Supreme Court not to take the case because the pleadings “do not contain many of facts that would be relevant to the materiality inquiry,” so it is therefore is unclear “exactly what the government knew and when.” In addition, DOJ asserted that the Supreme Court “decided Escobar after briefing had concluded in the Ninth Circuit, [so] the facts and arguments relevant to the materiality analysis were less developed than they would be in a case pleaded and litigated after that decision.”

DOJ also staked out the government’s view of the widely litigated materiality standard under the FCA, particularly the significance of the government’s continued payment after being made aware of a defendant’s purported misconduct. DOJ supported the Ninth Circuit’s decision, and asserted that “the government’s continued payment for a product, after learning that the manufacturer has made misrepresentations to the government regarding that product, can be strong evidence that the misrepresentations were not material to the government’s payment decisions,” but also that “under the circumstances of this case,” “continued government payments did not by itself require dismissal of respondents’ claims at the pleading stage.” DOJ advocated that courts should not put too much weight on the government’s continued payment of claims. DOJ argued that the Ninth Circuit properly “recognized that the determination whether a misstatement is material ‘turns on a number of factors,’ including the government’s payment decisions.” According to DOJ, “[m]ost significantly, the court of appeals recognized that, under Escobar, the relevance of a government payment decision turns on whether the government had “actual knowledge” of violations at the time of payment.” (emphasis added).

DOJ will seek to dismiss relators’ case if remanded

Although DOJ supports the Ninth Circuit’s decision—which would have allowed relators’ FCA case to move forward—DOJ advised the Supreme Court that further review of this case is not warranted on the Escobar materiality issue, and that DOJ will seek to dismiss relators’ claims on remand under its rarely-invoked statutory power to dismiss declined qui tam FCA cases.

Under the FCA, the United States is authorized to dismiss qui tam suits over a relator’s objection. 31 U.S.C. 3730(c)(2)(A). DOJ explained in its amicus brief that “the government’s authority to dismiss qui tam suits is not limited to circumstances where the defendant is entitled to dismissal on legal or factual grounds, but may be exercised whenever the government concludes that continued prosecution of the suit is not in the public interest.”

Under this authority, DOJ told the Supreme Court that “if this case is remanded to the district court, the government will move to dismiss respondents’ suit under Section 3730(c)(2)(A).”  DOJ made this determination “based in part on the government’s thorough investigation of [relators’] allegations and the merits thereof.” The burden on the FDA also factored in, with DOJ stating that “if this suit proceeded past the pleading stage, both parties might file burdensome discovery and Touhy requests for FDA documents and FDA employee discovery (and potentially trial testimony), in order to establish ‘exactly what the government knew and when,” which would distract from the agency’s public-health responsibilities.’” DOJ therefore decided that “allowing this suit to proceed to discovery (and potentially a trial) would impinge on agency decision making and discretion and would disserve the interests of the United States.”  We note that, if this case is remanded (with or without Supreme Court review), and DOJ seeks dismissal, relators are entitled to a hearing on DOJ’s request for dismissal, under the Ninth Circuit’s Sequoia Orange standard.


DOJ’s amicus brief highlights the continued FCA litigation over the meaning of “materiality,” which has resulted in somewhat different standards. As more FCA materiality cases reach the Supreme Court, we anticipate that the Court will eventually weigh in (though DOJ has asserted that this is not the right case).

DOJ’s notification to the Supreme Court that it will seek to dismiss relators’ case—particularly at this stage of the appeal—shocked observers.  We are beginning to observe, and do expect, that under the so-called “Granston memo,” issued in January 2018, DOJ will use its authority more often in district court at early stages of litigation. As we explained, DOJ’s Civil Fraud section instructed in the “Granston memo” that all government FCA litigators consider whether declined qui tam actions should be dismissed under the Department’s authority in Section 3730(c)(2)(A) of the FCA. The central theme of this policy is that dismissal of qui tam actions is warranted when it is in the federal interest to do so, and the policy clearly sets out seven federal interests.

At this point, it remains to be seen whether the Supreme Court will grant certiorari in this case and grapple with materiality under Escobar, or if it will decline to do so, as DOJ suggests, resulting in remand of the case. In any event, the statement by DOJ appears to reflect DOJ’s increasing willingness to seek to dismiss declined cases and that DOJ is mindful of the discovery burden on the agency of a relator trying to prove an FCA case.

©1994-2020 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume VIII, Number 337


About this Author

Brian P. Dunphy, Pharmaceutical Attorney, Mintz Levin, Anti-Kickback Lawyer,Health Care Enforcement & Investigations Health Care Compliance, Fraud & Abuse, and Regulatory Counseling Complex Commercial Litigation

Brian has handled a wide range of health care litigation matters, government investigations, and voluntary disclosures for an array of health care providers, life sciences companies, and private equity funds and their portfolio companies. He defends clients against allegations of false claims for payment to the government, in SEC investigations and enforcement proceedings, and represents clients in complex business disputes. Brian also counsels clients on health care regulatory issues, including telemedicine laws, compliance with the federal Physician Payments Sunshine Act and analogous...

Laurence J. Freedman, Litigation Attorney, Mintz, Enforcement Defense Law

Larry has a deep understanding of what drives government enforcement actions, and how to defend against them, in the health care and life sciences industries. As a trial lawyer and then official in the Civil Fraud Section of the U.S. Department of Justice, he litigated and supervised hundreds of False Claims Act and qui tam cases nationally. In his litigation practice, Larry has successfully represented hospitals and health care systems, laboratories, pharmaceutical and device manufacturers, and health care executives against fraud and abuse allegations and investigations brought by federal and state agencies. He is consistently recognized among the nation’s leading health care defense attorneys.

Larry’s health care and life sciences litigation practice focuses on defending clients against allegations and investigations of fraud and abuse involving governmental programs. He is highly experienced in representing clients against actions brought by federal and state agencies including the US Department of Justice (DOJ), the Department of Health and Human Services Office of the Inspector General (HHS OIG), the United States Attorneys’ Offices, and state OIGs and Medicaid Fraud Control Units (MFCUs).

Larry’s practice is based on his 24-years of experience handling complex civil litigation, often in the context of parallel proceedings, and achieving global resolutions. In addition to enforcement defense, Larry counsels clients through internal investigations, corporate compliance, investor due diligence reviews, and health care bankruptcies involving governmental liabilities. His clients include hospitals and health systems, dialysis providers, clinical laboratories, medical equipment companies, pharmaceutical and device manufacturers, and health care executives.

Prior to private practice, Larry served as an Assistant Director with the Civil Fraud Section of the DOJ and focused solely on the False Claims Act and its qui tam provisions. At DOJ he supervised hundreds of qui tam cases filed in US district courts throughout the country, was part of the leadership team for the pharmaceutical enforcement initiative, and managed high-profile actions often involving multiple US Attorneys’ Offices and federal agencies.

Prior to his position as Assistant Director, Larry served with the Civil Fraud Section as a trial attorney focused on health care fraud and defense procurement. He co-led the notable investigation and prosecution of national independent clinical laboratories known as “Operation LABSCAM.” For his achievements, Larry was highly-recognized by the Attorney General with the Department’s highest and second highest awards, as well as multiple awards from the HHS OIG and the MFCUs.

Following law school, Larry served as a law clerk for the Honorable Richard Cardamone of the U.S. Court of Appeals for the Second Circuit.